Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Reducing clinic visits can support retention in HIV care, African studies show

Interventions which reduce the need for people to attend clinics are proving highly successful in retaining people in care and supporting adherence to HIV medication in southern

Published
26 July 2016
By
Keith Alcorn
Early HIV treatment: mothers say they need time to think

Findings from the first randomised controlled trial to date evaluating postpartum antiretroviral therapy (ART) for women with high CD4 cell counts (over 400 cells/mm3) highlight a critical need

Published
26 July 2016
By
Carole Leach-Lemens
Women with HIV have higher risk of loss to follow-up and death after delivery

Despite the widespread implementation of Option B+ (lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women regardless of CD4 cell count) postpartum HIV-positive women remain at higher risk

Published
26 July 2016
By
Carole Leach-Lemens
Once-daily raltegravir works as well as twice-daily for initial HIV treatment

A new formulation of the integrase inhibitor raltegravir (Isentress) taken once daily suppressed HIV viral load as well as the older formulation taken twice a day in people

Published
26 July 2016
By
Liz Highleyman
Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment

A two-drug regimen of dolutegravir and the well-tolerated NRTI lamivudine led to sustained viral suppression for most people starting antiretroviral therapy (ART) for the first time in a

Published
25 July 2016
By
Liz Highleyman
Earlier HIV treatment is not over-burdening health services

Earlier treatment initiation is not overwhelming rural health services in South Africa, but changes in treatment eligibility criteria alone may not increase the number of people on

Published
22 July 2016
By
Keith Alcorn
Long-acting injectable drugs work well for HIV maintenance therapy

Two long-acting injectable antiretrovirals – cabotegravir and rilpivirine – administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load,

Published
22 July 2016
By
Liz Highleyman
World’s largest study of HIV self-testing gets off the ground

Early data from STAR, the largest study yet of HIV self-testing, suggests that there is a strong demand for self-testing in rural Zimbabwe, the 21st International AIDS

Published
22 July 2016
By
Roger Pebody
Immune-Enhancing Treatment May Destabilize HIV Reservoirs

Findings presented at the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa, suggest that combining ART with an immune-enhancing treatment may destabilize viral reservoirs in macaques infected with simian immunodeficiency virus (SIV), the monkey equivalent of HIV.

Published
21 July 2016
From
NIAID
Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study

The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well

Published
21 July 2016
By
Liz Highleyman
← First12345...422Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close